person · Reporting owner
Maccecchini Maria-Luisa
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annovis Bio, Inc.ANVS · Entity 7001 | Director · President & CEO | October 28, 2025 | November 12, 2025 |
| Lantern Pharma Inc.LTRN · Entity 7525 | Director | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annovis Bio, Inc.
Report date October 28, 2025 · Filed November 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,212,020 |
Reported balance
After 2025-10-28 transaction · row 1
1 source rowRow 1 · 2025-10-28 · Purchase · Acquired 97,561 · Balance 1,212,020 |
Lantern Pharma Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.49 · Expires 2036-01-08 | Direct | 25,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 25,000 · Balance 25,000 F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.49 · Expires 2036-01-08 | Direct | 21,152 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 21,152 · Balance 21,152 F2: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.
F2: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 21,152 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001493152-26-002025 · ownership.xml · derivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,152 Underlying: Common Stock · 21,152 shares Expires 2036-01-08 F2 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001493152-26-002025 · ownership.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026. Read SEC document |
| October 28, 2025 Filed Nov 12, 2025 14:19 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 97,561 | $2.05 | $200,000.05 |
DisclosureSEC source: 0001104659-25-109906 · tm2527472-3_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,212,020 Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 10:00 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 46,000 | $3.37 | $155,020.00 |
DisclosureSEC source: 0001104659-25-056578 · tm2517204-1_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,114,459 Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028185 · ownership.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options will vest and first become exercisable in equal monthly increments over a 36-month period commencing August 15, 2024. Read SEC document |
| March 31, 2024 Filed Jul 3, 2024 21:16 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-077834 · tm2417696-3_4seq1.xml · nonDerivative · entry 3 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,068,459 F1 · security: Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. Read SEC document |
| March 31, 2024 Filed Jul 3, 2024 21:16 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-077834 · tm2417696-3_4seq1.xml · nonDerivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,078,459 F1 · security: Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. Read SEC document |
| March 28, 2024 Filed Jul 3, 2024 21:16 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-077834 · tm2417696-3_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,088,459 F1 · security: Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 19:30 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 41,186 | $6.07 | $249,999.02 |
DisclosureSEC source: 0001104659-23-120302 · tm2331305-3_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,098,675 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:23 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 40,970 | $6.10 | $249,917.00 |
DisclosureSEC source: 0001104659-23-120762 · tm2331305-11_4aseq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,098,459 Read SEC document |
| November 17, 2023 Filed Jul 3, 2024 21:16 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 108,800 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-24-077834 · tm2417696-3_4seq1.xml · derivative · entry 5 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,800 Underlying: Common Stock · 108,800 shares Expires 2033-11-17 F4 · security: The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved. F5 · derivative.exercise_date: The stock option shall vest immediately. Read SEC document |
| November 17, 2023 Filed Jul 3, 2024 21:16 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 252,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-24-077834 · tm2417696-3_4seq1.xml · derivative · entry 4 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 Underlying: Common Stock · 252,000 shares Expires 2033-11-17 F2 · security: On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. F3 · derivative.exercise_date: Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:34 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-050393 · tm2313853-1_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,057,489 Read SEC document |
| April 07, 2023 Filed Apr 12, 2023 01:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 20,000 | $12.61 | $252,200.00 |
DisclosureSEC source: 0001104659-23-044202 · tm2312464-1_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,060,489 Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:11 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionStock Option (right to buy) · Derivative | 52,755 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-23-014610 · tm231947-2_4seq1.xml · derivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,755 shares Expires 2027-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares underlying the option are fully vested and exercisable. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:11 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionCommon Stock | 52,755 | $0.14 | $7,385.70 |
DisclosureSEC source: 0001104659-23-014610 · tm231947-2_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 22:43 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 21,312 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0001104659-23-005481 · tm234043-6_4seq1.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,312 Underlying: Common Stock · 21,312 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option shall vest in eight consecutive quarterly installments of 2,664 shares each on the 18th day of April, July, October and January of each year, commencing April 18, 2023, and continuing through January 18, 2025. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:57 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 3,200 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001493152-22-029456 · ownership.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires 2032-10-19 F1 · derivative.exercise_date: The Option is granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. 356 shares of the Option vested on the day of grant, with the remaining Option shares to vest in equal monthly installments commencing November 8, 2022 with last vesting on June 8, 2025. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 02:08 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionStock Option (right to buy) · Derivative | 32,959 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-22-005059 · tm221949-7_4seq1.xml · derivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,755 Underlying: Common Stock · 32,959 shares Expires 2027-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares underlying the option are fully vested and exercisable. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 02:08 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionCommon Stock | 32,959 | $0.14 | $4,614.26 |
DisclosureSEC source: 0001104659-22-005059 · tm221949-7_4seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:42 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 19,894 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0001104659-22-001640 · tm221949-3_4seq1.xml · derivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,894 Underlying: Common Stock · 19,894 shares Expires 2032-01-03 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in two equal installments of 9,947 shares on March 31, 2022 and March 31, 2023. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:42 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 83,400 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0001104659-22-001640 · tm221949-3_4seq1.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,400 Underlying: Common Stock · 83,400 shares Expires 2032-01-03 F1 · derivative.exercise_date: The stock option shall vest in eight consecutive quarterly installments of 10,425 shares each on the 3rd day of April, July, October and January of each year, commencing April 3, 2022, and continuing through January 3, 2024. Read SEC document |
| December 20, 2021 Filed Jan 19, 2022 02:07 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005057 · tm221949-8_5seq1.xml · nonDerivative · entry 5 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,775 F2 · shares: Charitable gift. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:00 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 145,305 | $0.00 Strike: $20.97 | $0.00 |
DisclosureSEC source: 0001104659-21-147673 · tm2134914-1_4seq1.xml · derivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,305 Underlying: Common Stock · 145,305 shares Expires 2031-12-06 F2 · derivative.exercise_date: The stock option shall vest in two installments: (i) the first installment of 72,653 shares on March 31, 2022 and (ii) a second and final installment of 72,652 shares on March 31, 2023, provided that the reporting person continues to be employed by the issuer on the applicable vesting date. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:00 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 112,995 | $0.00 Strike: $20.97 | $0.00 |
DisclosureSEC source: 0001104659-21-147673 · tm2134914-1_4seq1.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,995 Underlying: Common Stock · 112,995 shares Expires 2031-12-06 F1 · derivative.exercise_date: The stock option is 100% vested. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 20:00 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 18,000 | $27.61 | $496,980.00 |
DisclosureSEC source: 0001415889-21-004862 · form4-10132021_011036.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,775 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $27.58 to $27.64, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 22:27 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 41,700 | $0.00 Strike: $102.85 | $0.00 |
DisclosureSEC source: 0001104659-21-090743 · tm2121908-3_4seq1.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,700 Underlying: Common Stock · 41,700 shares Expires 2031-07-07 F1 · derivative.exercise_date: The stock option shall vest in eight substantially equal quarterly installments beginning October 7, 2021, provided that the reporting person continues to be employed by the issuer on the applicable vesting date. Read SEC document |
| July 01, 2021 Filed Jan 19, 2022 02:07 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005057 · tm221949-8_5seq1.xml · nonDerivative · entry 4 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,775 F2 · shares: Charitable gift. Read SEC document |
| July 01, 2021 Filed Jan 19, 2022 02:07 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005057 · tm221949-8_5seq1.xml · nonDerivative · entry 3 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,775 F2 · shares: Charitable gift. Read SEC document |
| July 15, 2020 Filed Jan 19, 2022 02:07 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005057 · tm221949-8_5seq1.xml · nonDerivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,775 F1 · kind: Charitable gift that was not previously reported in a Form 5 for the fiscal year ended December 31, 2020. F2 · shares: Charitable gift. Read SEC document |
| April 27, 2020 Filed Jan 19, 2022 02:07 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005057 · tm221949-8_5seq1.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,775 F1 · kind: Charitable gift that was not previously reported in a Form 5 for the fiscal year ended December 31, 2020. F2 · shares: Charitable gift. Read SEC document |
| April 09, 2020 Filed Apr 14, 2020 00:06 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001104659-20-046066 · a4.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-04-09 Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionSeries A Preferred Stock · Derivative | 1,068,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-010939 · a4.xml · derivative · entry 5 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 762,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F3 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F3 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionSeries A-1 Preferred Stock · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-010939 · a4.xml · derivative · entry 4 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.expiration_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 762,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-010939 · a4.xml · nonDerivative · entry 3 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 7,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-010939 · a4.xml · nonDerivative · entry 2 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 1,600 | $6.00 | $9,600.00 |
DisclosureSEC source: 0001104659-20-010939 · a4.xml · nonDerivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,942 F1 · shares: The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.